Tag:

Pradaxa

Latest Headlines

Latest Headlines

Boehringer Ingelheim revenue slide cushioned by Pradaxa sales jump

Pradaxa may not be leading the new-age anticoagulant market, but it's certainly leading Boehringer Ingelheim's growth efforts. The blockbuster med made significant gains in 2013 to help offset currency effects and keep operating income up in the face of dwindling sales, the company said Tuesday.

UPDATED: Boehringer's Pradaxa fights to regain ground with new clot-fighting approval

Boehringer Ingelheim, determined not to let clot-fighter Pradaxa be outdone by Bayer and Johnson & Johnson's Xarelto, has added a couple of new uses to the drug's label, snagging the FDA's okay to treat deep vein thrombrosis (DVT) and pulmonary embolism (PE) in some patients. But it still has a long way to go--and some safety concerns to dispel--before it can retake the anticoagulant throne.

Pradaxa, Xarelto makers dispute purported Eliquis safety edge

Is Pfizer and Bristol-Myers Squibb's Eliquis really safer than its competitors? A recent analysis of FDA adverse events reports suggested that it is.

Boehringer Ingelheim withheld Pradaxa data from FDA, lawsuit files show

Drugmakers should clean out their data closets and turn over to regulators every bit of research and analysis they have, according to some healthcare experts, who point to documents released in litigation against Boehringer Ingelheim, with the company's blockbuster anticoagulant Pradaxa as prime evidence.

Boehringer says it's fighting 2,000 lawsuits over Pradaxa safety

Pradaxa has become a bigger legal headache for Boehringer Ingelheim. The German drugmaker says it's facing more than 2,000 lawsuits in the U.S., filed by patients claiming the anticoagulant drug caused severe or fatal bleeding.

Pradaxa files show drug marketers weighing in on how to communicate the drug's risks

Recently unsealed company documents that are part of litigation over the bleeding risks of Boehringer Ingelheim's blockbuster blood thinner Pradaxa show that officials wanted to soften, or even kill, an internal report that suggested a small group of patients would benefit from regular blood monitoring for bleeding risks, The New York Times reports.

UPDATED: FDA returns for look at risk of Boehringer Ingelheim's Pradaxa

FDA and clinical reviews have not found the chances of bleeding to be any greater for Boehringer Ingelheim's Pradaxa than for warfarin, but it continues to top the list for adverse reaction reports, and the FDA has decided to do another data dive into how the two compare.

Daiichi clot-fighter aces study, but can it compete with Pradaxa, Xarelto and Eliquis?

The good news for Daiichi Sankyo: Its new anticoagulant drug matched the old standard-issue drug warfarin at preventing stroke and blood clots. And as far as safety goes, edoxaban beat warfarin by a significant stretch. That's an entree into the warfarin-alternative market, expected to grow to $10 billion over the next several years.

Safety group flags bleeding reports on Pradaxa, Xarelto and old standby warfarin

The Institute for Safe Medication Practices has flagged its latest set of side-effect reports to the FDA--and once again, anticoagulant drugs are at the top. Boehringer Ingelheim's Pradaxa, a new-generation pill, and the old standard therapy warfarin together accounted for more than 1,100 of the adverse events reported direcctly to the FDA.

Which new drugs promise to shake up markets the most?

Every drugmaker dreams of developing a drug so important that it shakes up an entire market. And it happens--just think of Johnson & Johnson's Zytiga, the prostate cancer drug that has not only grown by leaps and bounds, but arguably nudged aside Dendreon's competing treatment, Provenge. Want new examples? That's what Motley Fool offers today.